In HCC, the upregulation of ligands (Wnt1, Wnt3A, etc.)and FZD receptors (FZD2 and FZD7), along with frequent CTNNB1 mutations, is linked to early tumorigenesis, elevated risk of recurrence, and worse clinical outcomes. Here, WNT1 is linked to hepatocellular carcinoma.